Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Launched by YALE UNIVERSITY · Jul 14, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Stereotactic Body Radiation Therapy (SBRT) for patients with metastatic renal cell carcinoma who are experiencing oligoprogression. Oligoprogression means that while most of the cancer is stable, a few specific areas (between 1 to 5 lesions) are getting worse despite ongoing treatment with immune checkpoint inhibitors (ICIs). The main goal of the study is to see how long patients can live without their cancer getting worse after receiving SBRT to these specific areas.

To participate in the trial, patients need to be at least 18 years old and have a confirmed diagnosis of metastatic renal cell carcinoma. They should have received ICI treatment for at least three months before showing signs of oligoprogression and be in generally good health (with a life expectancy of more than six months). Participants can expect to receive targeted radiation therapy to the areas of concern and will be monitored closely for their progress. If you or a loved one meet these criteria and are interested in exploring this treatment option, it could be a valuable opportunity to help manage the cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• In order to be eligible for participation in this trial, the subject must:
• • 1. Be willing and able to provide written informed consent/assent for the trial
• • 2. Be ≥ 18 years of age on day of signing informed consent.
• • 3. Have histologically confirmed renal cell carcinoma with metastatic disease detected on imaging. Biopsy of metastasis is preferred but not required
• • 4. The subject has a performance status of 0, 1, or 2 on the ECOG Performance Scale
• • 5. The life expectancy is \> 6 months
• • 6. The most recent systemic therapy must be an ICI-containing regimen, delivered for at least 3 months prior to development of oligoprogressive lesions, with the last dose received within 3 months of trial enrollment.
• 7. Oligoprogression - defined as documented progression in up to 5 individual lesions with no previous local therapy to those sites using one of the following criteria:
• • 7.1 RECIST 1.1 7.1.1 At least a 20% increase in the sum of diameters of target lesions (long axis for non-nodal lesions, short axis for nodal lesions), using the previous imaging as a baseline 7.1.2 The sum of all diameters must demonstrate an absolute increase of at least 5 mm 7.1.3 The appearance of at least one new unequivocal lesion 7.2 PERCIST 7.2.1 SUVpeak, normalized to lean body mass (SUL) increase by at least 30% and increase by at least 0.8 SUL of the target lesion 7.2.2 Development of at least one new lesion 7.2.3 Increase in target lesion size by 30% 7.2.4 Unequivocal progression of nontarget lesions 7.3 Progressive enlargement of a known metastasis on 2 consecutive imaging studies at least 2 months apart with a minimum 5 mm increase in size 7.4 Development of a new soft tissue metastatic lesion at least 5 mm in size or any new bone metastasis
• • 8. There is no restriction on the total number of metastases
• • 9. Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 28 days of protocol treatment
• • Table 4 Adequate Organ Function Laboratory Values
• • System Laboratory Value
• • Hematological
• • Absolute neutrophil count (ANC) ≥ 1,500 /mcL Platelets ≥ 75,000 / mcL Hemoglobin ≥ 9 g/dL
• • Renal - IF SBRT will be delivered to a lesion in or abutting the kidney
• • Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR Measured or calculated\* creatinine clearance (GFR can also be used in ≥30 mL/min for subject with creatinine place of creatinine or CrCl) levels \> 1.5 X institutional ULN
• • Hepatic - IF SBRT will be delivered to a lesion in or abutting the liver
• • Serum total bilirubin ≤ 1.5 X ULN Direct bilirubin Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR
• • 5 X ULN for subjects with liver metastases
• • Creatinine clearance should be calculated per institutional standard
• • 10. Able to be treated with SBRT at a Yale radiation oncology facility
• • 11. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of SBRT. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• • 12. Female subjects of childbearing must use an effective form of birth control during this study. Acceptable and highly effective birth control methods include intra-uterine hormone releasing system as well as other methods of birth control including consistent use of an approved oral contraceptive (birth control pill), an implantable contraceptive, an injectable contraceptive, a double-barrier method, or true abstinence. Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days prior to the screening visit and continue for 120 days after last dose of study drug. (Reference Section 5.7)
• • 13. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy
• Exclusion Criteria:
• • The subject must be excluded from participating in the trial if the subject
• • 1. Has had radiation therapy within 2 weeks of the first protocol treatment.
• • 2. Has brain-only oligoprogression. subjects with brain and systemic oligoprogression can still be considered, however treatment of brain metastases will be per standard of care prior to receiving study SBRT.
• • 3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment. The use of lowdose steroids for management of chronic conditions is allowed (up to 12mg prednisone orally per day or the equivalent).
• • 4. Has had prior radiation therapy within 2 weeks of the first protocol treatment.
• • 5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
• • 6. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an example of an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Those with a history of hypothyroidism who are now stable on hormone replacement will not be excluded. Those with Sjorgen's syndrome will not be excluded from the study.
• • 7. Has a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or underlying lung disease that according to the treating physician makes the patient ineligible.
• • 8. Has an active infection requiring systemic therapy.
• • 9. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
• • 10. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected).
• • 11. Has received a live vaccine within 30 days prior to the first protocol treatment.
• • 12. Has serious medical comorbidities precluding radiotherapy. These include subjects with connective tissue diseases such as lupus or scleroderma, Crohn's disease in subjects where the GI tract will receive radiation
• • 13. Substantial overlap with a previously treated radiation volume. Prior radiotherapy is allowed as long as the composite plan meets dose constraints